Fluoroquinolone resistance among invasive viridans group streptococci and Streptococcus bovis isolated in Spain

International Journal of Antimicrobial Agents

Volumn 29, Issue 4, 2007, Pages 478-480

  Rodríguez Avial, Iciar ^a   Rodríguez Avial, Carmen ^a   Culebras, Esther ^a   Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG SENSITIVITY; IN VITRO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL; SPAIN; STREPTOCOCCUS; STREPTOCOCCUS BOVIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; SPAIN; STREPTOCOCCUS BOVIS; VIRIDANS STREPTOCOCCI;

EID: 33847421745     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.12.006     Document Type: Letter

References (9)

1. Gershon A.S., de Azavedo J.C.S., and McGeer A. Activities of new fluoroquinolones, ketolides and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada. Antimicrob Agents Chemother 46 (2002) 1553-1556
2. Diekema D.J., Beach M.L., Pfaller M.A., and Jones R.N. SENTRY Participants Group. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect 7 (2001) 152-157
3. de Azavedo J.C.S., Trpeski L., Pong-Porter S., et al. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. Antimicrob Agents Chemother 43 (1999) 2299-2301
4. Balsalobre L., Ferrandiz M.J., Liñares J., Tubau F., and de la Campa A.G. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 47 (2003) 2072-2081
5. Coykendall A.L. Classification and identification of the viridans streptococci. Clin Microbiol Rev 2 (1989) 315-328
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th Informational Supplement. M100-S15. Wayne, PA: CLSI; 2005.
7. González I., Georgiu M., Alcaide F., Balas D., Liñares J., and de la Campa A.G. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 42 (1998) 2792-2798
8. Muñoz R., and de la Campa A.G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 40 (1996) 2252-2257
9. Marron A., Carratalá J., Alcaide F., Fernández-Sevilla A., and Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 47 (2001) 87-91